Project Grant R01CA297797
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $470K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Cancer Institute awarded The Washington University $155,500 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the direct and indirect costs of fertility preservation options for adolescent and young adult cancer survivors, including out-of-pocket fees, transportation, and time off work for parents and caregivers. The research addresses financial hardship among adolescent and young adult cancer survivors, examining how cost...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $771,811 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify small molecule activators of type I interferon signaling for cancer treatment. The research focuses on discovering and developing small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the type I interferon response through negative feedback regulation. Prior work...
- The National Cancer Institute awarded The Leland Stanford Junior University $258,945 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to adapt and pilot test Roadmap to Parenthood, an evidence-based digital decision aid and planning tool for family building after cancer. Roadmap was originally developed for women who completed gonadotoxic cancer treatment and demonstrated improvements in knowledge, self-efficacy, decisional conflict, and patient-provider...
- Grant Award Summary The National Cancer Institute awarded University of California, San Diego a Project Grant of $159,500 under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period July 1, 2025 through June 30, 2027. This research project investigates the role of Signal Transducer and Activator of Transcription (STAT) in heterochromatin initiation, with the objective of advancing understanding of heterochromatin formation mechanisms and their implications for tumor...
- The National Cancer Institute awarded the University of California, San Diego $663,998 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct mechanistic research on targeting the Type I interferon pathway to improve cancer therapy efficacy. The research investigates how ubiquitin specific protease 18 (USP18) negatively regulates interferon signaling in cancer cells and tests whether blocking USP18-mediated suppression of the interferon response can enhance the...
- The National Cancer Institute awarded the University of California, Santa Cruz $128,940 under the Cancer Research Manpower program (CFDA 93.398) on January 12, 2026, to support research determining the effects of pregnancy and aging on the mammary gland and breast cancer risk reduction. The funded research investigates how early full-term pregnancy reduces breast cancer risk by altering the molecular and cellular processes in mammary epithelial cells (MECs). The project uses single-cell RNA...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $132,618 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support mentored training for a PhD student in epidemiology at UCSF to become a researcher in cancer health disparities. The award funds a Ruth L. Kirschstein National Research Service Award (F31) that provides the trainee with expertise in translational research, geospatial data analysis, and causal inference...
- The National Cancer Institute awarded Children's Hospital Los Angeles $8.473 million on September 10, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a patient navigation intervention designed to improve transition success among multiply disadvantaged young adult survivors of childhood cancer. The intervention addresses a documented gap in survivorship care: while childhood cancer survival rates exceed 85 percent, treatment-related late effects...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $988,224 Project Grant to the University of California, San Diego effective September 1, 2025, through August 31, 2029, under the Cancer Treatment Research program (CFDA 93.395). This funding supports clinical research activities advancing therapeutic strategies for head and neck cancer patients who are medically unfit for standard treatment, with particular focus on older populations and medically underserved...
- The National Cancer Institute awarded the University of California Irvine $639,707 on June 20, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the mechanisms and functional roles of PARP1 hyperactivation in cancer. The award funds research into how ATR inhibitors enhance cancer cell sensitivity to PARP inhibitors through PARP1 hyperactivation. The project will examine why DNA cleavage by APE1 is the essential step leading to PARP1 hyperactivation...